Crossmark

An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments

Crossref DOI link: https://doi.org/10.1186/s41687-019-0100-y

Published Online: 2019-03-04

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Staunton, Hannah http://orcid.org/0000-0003-4662-6490
Willgoss, Tom

Nelsen, Linda

Burbridge, Claire

Sully, Kate

Rofail, Diana

Arbuckle, Rob
Funding

Funding for this research was provided by:

F. Hoffmann-La Roche
License Information

Text and Data Mining valid from 2019-03-04
More Information

Article History

Received: 6 June 2018

Accepted: 21 January 2019

First Online: 4 March 2019

Consent for publication

: Not applicable.

: Hannah Staunton and Tom Willgoss are employees and shareholders of Roche Products Ltd.Diana Rofail was an employee and shareholder of Roche Products Ltd. at the time this manuscript was written.Linda Nelsen is an employee of GlaxoSmithKline.Claire Burbridge is an employee of Clinical Outcomes Solutions.Rob Arbuckle and Kate Sully are employees of Adelphi Values.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.